Welcome to LookChem.com Sign In|Join Free

CAS

  • or

319474-37-8

Post Buying Request

319474-37-8 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

319474-37-8 Usage

Structure

Indazole ring, carboxamide group, 4-hydroxyphenyl group

Derivative

Indazole

Potential applications

Medicinal chemistry, pharmaceutical drug development

Biological activity

Unclear, requires further research for full understanding

Check Digit Verification of cas no

The CAS Registry Mumber 319474-37-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,1,9,4,7 and 4 respectively; the second part has 2 digits, 3 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 319474-37:
(8*3)+(7*1)+(6*9)+(5*4)+(4*7)+(3*4)+(2*3)+(1*7)=158
158 % 10 = 8
So 319474-37-8 is a valid CAS Registry Number.

319474-37-8SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 17, 2017

Revision Date: Aug 17, 2017

1.Identification

1.1 GHS Product identifier

Product name N-(4-hydroxyphenyl)-3-formyl-1H-indazole-6-carboxamide

1.2 Other means of identification

Product number -
Other names -

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:319474-37-8 SDS

319474-37-8Downstream Products

319474-37-8Relevant articles and documents

Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use

-

, (2008/06/13)

Indazole compounds that modulate and/or inhibit the activity of certain protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating tyrosine kinase signal transduction and thereby modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 319474-37-8